Venus Remedies is currently trading at Rs. 250.00, up by 7.85 points or 3.24% from its previous closing of Rs. 242.15 on the BSE.
The scrip opened at Rs. 245.95 and has touched a high and low of Rs. 253.90 and Rs. 244.25 respectively. So far 4351 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 327.80 on 05-Dec-2012 and a 52 week low of Rs. 155.00 on 27-Mar-2012.
Last one week high and low of the scrip stood at Rs. 280.00 and Rs. 230.00 respectively. The current market cap of the company is Rs. 239.65 crore.
The promoters holding in the company stood at 34.22% while Institutions and Non-Institutions held 14.45% and 51.33% respectively.
Venus Remedies has launched its first OTC product ‘Ezenus’, a stress reliever. Ezenus is a unique medical nutrition product which is absolutely safe, zero calorie, non-addictive, herbal candy, with clinically proven anti-stress activity. With the launch of Ezenus, the company is entering into the OTC segment for the first time. The company is hopeful that this novel research Ezenus will acquire 5% of the product 100 million dollar direct market of stress segment in India, other than lifestyle disorders, within 3 years of its launch.
Ezenus is world’s first anti stress product launched in easy to use candy form even suitable for diabetic patients. It is highly safe in acute stress management such as exam stress in children and in chronic stress like in alcoholic and smoking population, without change in life style by continuous detoxification and strong antioxidant activity.
Ezenus reduces more than 60% stress within 30 days without change in life style and significantly improves the quality of life in terms of physical, social, emotional and functional well- being. This breakthrough innovative product is suitable for all ages with safety established upto 10 times advised dose.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: